Global urine metabolomics in patients treated with first-line tuberculosis drugs and identification of a novel metabolite of ethambutol

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2257-2264

  Das, Mrinal Kumar ^a   Arya, Rakesh ^a   Debnath, Sanjita ^b   Debnath, Rahul ^b   Lodh, Anindita ^b   Bishwal, Subasa Chandra ^a,c   Das, Anjan ^b   Nanda, Ranjan Kumar ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

^b Agartala Government Medical College   (India)

^c SAMBALPUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBUTYRIC ACID; 2,2' (ETHYLENEDIIMINO) DIBUTYRIC ACID; 5 HYDROXYPYRAZINAMIDE; 5 HYDROXYPYRAZINOIC ACID; ACETYLISONIAZID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ETHAMBUTOL; ISONIAZID; ISONICOTINIC ACID; ISONICOTINURIC ACID; PYRAZINAMIDE; PYRAZINOIC ACID; UNCLASSIFIED DRUG; ALPHA-AMINOBUTYRIC ACID; AMINOBUTYRIC ACID DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHEMICAL STRUCTURE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LUNG TUBERCULOSIS; MALE; METABOLIC RATIO; METABOLOMICS; OBESITY; PRIORITY JOURNAL; SPUTUM CYTODIAGNOSIS; TIME OF FLIGHT MASS SPECTROMETRY; UNDERWEIGHT; URINALYSIS; VERY ELDERLY; BIOTRANSFORMATION; CASE CONTROL STUDY; INDIA; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; TUBERCULOSIS, PULMONARY; URINE;

ADULT; AGED; AGED, 80 AND OVER; AMINOBUTYRATES; ANTITUBERCULAR AGENTS; BIOTRANSFORMATION; CASE-CONTROL STUDIES; CHROMATOGRAPHY, GAS; ETHAMBUTOL; FEMALE; HUMANS; INDIA; ISONIAZID; MALE; METABOLOMICS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUBERCULOSIS, PULMONARY;

EID: 84963716209     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02586-15     Document Type: Article

References (38)

1. WHO. 2014. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland.
2. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 50:1170-1177. http://dx.doi.org/10.1128/AAC.50.4.1170-1177.2006.
3. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2011. Variability inthe population pharmacokineticsof isoniazidinSouth African tuberculosis patients. Br J Clin Pharmacol 72:51-62. http://dx.doi.org/10.1111/j.1365-2125.2011.03940.x.
4. Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildiz L, Çarpaner E. 2013. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients. Int J Tuberc Lung Dis 17:1442-1447. http://dx.doi.org/10.5588/ijtld.12.0771.
5. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R. 2013. Isoniazid, rifampin and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother 57:3614-3619. http://dx.doi.org/10.1128/AAC.02468-12.
6. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, Aarnoutse RE. 2013. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob Agents Chemother 57:3208-3213. http://dx.doi.org/10.1128/AAC.02599-12.
7. Jing Y, Zhu LQ, Yang JW, Huang SP, Wang Q, Zhang J. 21 September 2015. Population pharmacokinetics ofrifampicininChinese patients with pulmonary tuberculosis. J Clin Pharmacol http://dx.doi.org/10.1002/jcph.643.
8. Seng KY, Hee KH, Soon GH, Chew N, Khoo SH, Lee LS. 2015. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. Antimicrob Agents Chemother 59:6791-6799. http://dx.doi.org/10.1128/AAC.01244-15.
9. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R. 2010. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 54:1068-1074. http://dx.doi.org/10.1128/AAC.00447-09.
10. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA, AIDS Clinical Trials Group Team. 2005. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 41:1638-1647. http://dx.doi.org/10.1086/498024.
11. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis/jit352.
12. Gumbo T, Louie A, Deziel MR, Drusano GL. 2005. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 49:3178-3181. http://dx.doi.org/10.1128/AAC.49.8.3178-3181.2005.
13. Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AM, Satyanarayana S, Parmar M, Moonan PK, Lo TQ. 2015. Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB centre in India. PLoS One 10:e0135802. http://dx.doi.org/10.1371/journal.pone.0135802.
14. Azhar GS. 2012. DOTS for TB relapse in India: a systematic review. Lung India 29:147-153. http://dx.doi.org/10.4103/0970-2113.95320.
15. Kulkarni P, Akarte S, Mankeshwar R, Bhawalkar J, Banerjee A, Kulkarni A. 2013. Non-adherence of new pulmonary tuberculosis patients to anti-tuberculosis treatment. Ann Med Health Sci Res 3:67-74. http://dx.doi.org/10.4103/2141-9248.109507.
16. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. 2009. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-914. http://dx.doi.org/10.1038/nature07762.
17. Kell DB, Goodacre R. 2014. Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discov Today 19:171-182. http://dx.doi.org/10.1016/j.drudis.2013.07.014.
18. Chen C, Gonzalez FJ, Idle JR. 2007. LC-MS-based metabolomics in drug metabolism. Drug Metab Rev 39:581-597. http://dx.doi.org/10.1080/03602530701497804.
19. Banday KM, Pasikanti KK, Chan EC, Singla R, Rao KVS, Chauhan VS, Nanda RK. 2011. Use of urine volatile organic compoundstodiscriminate tuberculosis patients from healthy subjects. Anal Chem 83:5526-5534. http://dx.doi.org/10.1021/ac200265g.
20. Das MK, Bishwal SC, Das A, Dabral D, Badireddy VK, Pandit B, Varghese GM, Nanda RK. 2015. Deregulated tyrosine-phenylalanine metabolism in pulmonary tuberculosis patients. J Proteome Res 14:1947-1956. http://dx.doi.org/10.1021/acs.jproteome.5b00016.
21. Roboz J, Suzuki R, Yü TF. 1978. Mass fragmentographic determination of pyrazinamide and its metabolites in serum and urine. J Chromatogr 147:337-347. http://dx.doi.org/10.1016/S0021-9673 (00) 85145-6.
22. Mehmedagic A, Vérité P, Ménager S, Tharasse C, Chabenat C, André D, Lafont O. 1997. Determination of pyrazinamide and its main metabolites in rat urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 695:365-372. http://dx.doi.org/10.1016/S0378-4347 (97) 00175-8.
23. Ishizu S, Hashida C, Hanaoka T, Maeda K, Ohishi Y. 1995. N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. Jpn J Cancer Res 86:1179-1181. http://dx.doi.org/10.1111/j.1349-7006.1995.tb03312.x.
24. Xia J, Sinelnikov IV, Han B, Wishart DS. 2015. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res 43 (W1):W251-W257. http://dx.doi.org/10.1093/nar/gkv380.
25. Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R. 2015. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. BMC Infect Dis 15:126. http://dx.doi.org/10.1186/s12879-015-0862-7.
26. Lee SY, Jang H, Lee J-Y, Kwon K, Oh SJ, Kim SK. 2014. Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett 229:33-40. http://dx.doi.org/10.1016/j.toxlet.2014.06.006.
27. Ellard EA. 1976. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 19:610-625. http://dx.doi.org/10.1002/cpt1976195part2610.
28. Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Hu OY. 2013. A novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother 57:1685-1690. http://dx.doi.org/10.1128/AAC.01866-12.
29. Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE, III, Dartois V. 2015. Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance, and therapeutic alternatives. ACS Infect Dis 1:203-214. http://dx.doi.org/10.1021/id500028m.
30. Mahapatra S, Woolhiser LK, Lenaerts AJ, Johnson JL, Eisenach KD, Joloba ML, Boom WH, Belisle JT. 2012. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct. Antimicrob Agents Chemother 56:28-35. http://dx.doi.org/10.1128/AAC.05486-11.
31. Li F, Miao Y, Zhang L, Neuenswander SA, Douglas JT, Ma X. 2011. Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine. Drug Metab Pharmacokinet 26:569-576. http://dx.doi.org/10.2133/dmpk. DMPK-11-RG-055.
32. Bonn B, Masimirembwa CM, Aristei Y, Zamora I. 2008. The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition. Drug Metab Dispos 36:2199-2210. http://dx.doi.org/10.1124/dmd.108.022376.
33. Peets EA, Sweeny WM, Place VA, Buyske DA. 1964. The absorption, excretion and metabolic fate of ethambutol in man. Am Rev Respir Dis 90:51-58.
34. Hall RG, II, Swancutt MA, Meek C, Leff RD, Gumbo T. 2012. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 56:1502-1507. http://dx.doi.org/10.1128/AAC.05623-11.
35. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, Kakazu Y, Ishikawa T, Robert M, Nishioka T, Tomita M. 2006. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem 281:16768-16776. http://dx.doi.org/10.1074/jbc. M601876200.
36. Lee EJ, Kim SJ, Choung HK, Kim JH, Yu YS. 2008. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuroophthalmol 28:269-277. http://dx.doi.org/10.1097/WNO.0b01 3e31818e3c6b.
37. Geyer HL, Herskovitz S, Slamovits TL, Schaumburg HH. 2014. Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment. J Neuroophthalmol 34:257-258. http://dx.doi.org/10.1097/WNO.0000000000000141.
38. Yowtak J, Wang J, Kim HY, Lu Y, Chung K, Chung JM. 2013. Effect of antioxidant treatment on spinal GABA neurons in a neuropathic pain model in the mouse. Pain 154:2469-2476. http://dx.doi.org/10.1016/j.pain. 2013.07.024.